SCHEMBL20522807

SCHEMBL20522807

CN1N=C(c2cccs2)CC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
KDM4E B2RXH2 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 6/20 0.41
L3MBTL1 Q9Y468 3/20 0.39
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
GLA P06280 1/20 0.39
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GABRA1 P14867 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GABRA2 P47869 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14559414 0.80 CA12 (0.40) KMT2ALMNAALDH1A1GAAKDM4E
SCHEMBL14559411 0.76 MAPT (0.52) KMT2ALMNAALDH1A1GAAKDM4E
SCHEMBL14559418 0.75 KMT2A (0.44) KMT2ALMNAALDH1A1GAAKDM4E
SCHEMBL14559431 0.72 MAPT (0.47) KMT2ALMNAALDH1A1GAAKDM4E
SCHEMBL14559424 0.72 MEN1 (0.42) KMT2ALMNAALDH1A1GAAKDM4E
SCHEMBL14559430 0.72 KMT2A (0.58) KMT2ALMNAALDH1A1GAAKDM4E
SCHEMBL4625694 0.72 GAA (0.54) KMT2AALDH1A1GAAKDM4ESMN1; SMN2
SCHEMBL4343534 0.70 MAPT (0.38) GAAKDM4EL3MBTL1MAPTGABRA1
SCHEMBL5486157 0.70 MAPK1 (0.44) KMT2ALMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL7615015 0.69 GABRA1 (0.40) KMT2AALDH1A1KDM4ESMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11617738-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2023-04-04 US disclosed
US-20210196684-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2021-07-01 US disclosed
US-20210196684-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2021-07-01 US disclosed
US-10980781-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2021-04-20 US disclosed
US-10980781-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use PURDUE RESEARCH FOUNDATION (US) 2021-04-20 US disclosed
US-20200078336-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2020-03-12 US disclosed
WO-2018183587-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200078336-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE USP7, USP3, USP2 KMT2A 1830/4885LMNA 4461/4885ALDH1A1 647/4885
US-20210196684-A1 6-AMINO-2,4-DIHYDROPYRANO [2,3-C] PYRAZOLES AND METHODS OF USE USP7, USP3, USP2 KMT2A 1830/4885LMNA 4461/4885ALDH1A1 647/4885
US-10980781-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use USP7, USP3, USP2 KMT2A 1830/4885LMNA 4461/4885ALDH1A1 647/4885
US-11617738-B2 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use USP7, USP3, USP2 KMT2A 1830/4885LMNA 4461/4885ALDH1A1 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.